ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 484

Targeting the BTK-JAK Axis in Preclinical Models of Rat Collagen-Induced Arthritis with GS-4059 in Combination with a JAK Inhibitor

Julie Di Paolo1, Christian Franci2, Terry Gentzler1, Bernard Murray3 and Li Li4, 1Biology, Gilead Sciences, Foster City, CA, 2Biology, Gilead Sciences, Foster, CA, 3DMPK, Gilead Sciences, Foster City, CA, 4Gilead Sciences, South San Francisco, CA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: BTK, Janus kinase (JAK), kinase and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Animal Models - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:   Bruton’s Tyrosine Kinase (BTK) mediates signaling in hematopoietic cells important for the initiation and progression of rheumatoid arthritis (RA). GS-4059 is an oral, selective, irreversible BTK inhibitor being developed in RA. JAK inhibitors have demonstrated clinical efficacy in RA and exert their biological activity principally by blockade of proinflammatory cytokine signaling. Here we demonstrate that 1) the single agent activity of GS-4059 is efficacious in two different rat models of collagen-induced arthritis (CIA); 2) the combination of GS-4059 with a JAK inhibitor increases efficacy in a chronic CIA model; and 3) the activities of targeting BTK or JAK as single agents can be functionally differentiated.

Methods:  The in vivo efficacy of GS-4059 and a JAK inhibitor were tested alone or in combination in rat CIA model. In the chronic model, dosing was initiated at the peak of disease and continued into the chronic phase; making the test more indicative of late treatment effects in the highly destructive macrophage-mediated phase, rather than in the acute, early, neutrophil mediated phase of this model. Efficacy evaluations were based on animal body weights, daily ankle caliper measurements, ankle diameter (expressed as area under the curve), terminal hind paw weights, and histopathologic evaluation of ankles and knees. Anti-type II collagen antibody levels in terminal serum were analyzed, and PK was collected to evaluate the relationship to efficacy. Joint tissue RNA and protein were analyzed for transcriptional and protein modulation.

Results:  GS-4059 demonstrated dose-responsive efficacy in two rat CIA models. In the chronic model, administration of either GS-4059 or a JAK inhibitor showed efficacy on the clinical and histopathologic parameters. Combination therapy with GS-4059 and a JAK inhibitor showed significantly greater effects on paw weights, ankle swelling, and ankle histopathology scores than the single agents. Body weight loss was significantly inhibited in the combination therapy group, and weight was increased compared to the monotherapy arms, suggesting the combination treatment was more effective. Serum anti-type II collagen antibody (IgG) levels were significantly reduced in rats treated with the combination of GS-4059 and a JAK inhibitor. Knee ED-1 immunopositive osteoclast counts were significantly reduced in the animals treated with GS-4059 or the combination, but not in the single agent JAK inhibitor group, highlighting functionally distinct effects of BTK or JAK inhibition. PK analysis of GS-4059 and the JAK inhibitor showed serum exposure levels similar to those achieved in human studies.

Conclusion:  GS-4059 is a novel BTK inhibitor that displayed in vivo therapeutic efficacy in the acute and chronic rat CIA models. Combining GS-4059 with a JAK inhibitor significantly improved clinical and histopathology scores, and reduced body weight loss in the rat CIA model, at exposures achieved in humans. These data suggest that simultaneously targeting BTK and JAK can provide an efficacious therapy for inflammatory diseases.


Disclosure: J. Di Paolo, Gilead Sciences, Inc, 1,Gilead Sciences, Inc, 3; C. Franci, Gilead Sciences, 1; T. Gentzler, Gilead Sciences, 1; B. Murray, Gilead Sciences, 1; L. Li, Gilead, 3.

To cite this abstract in AMA style:

Di Paolo J, Franci C, Gentzler T, Murray B, Li L. Targeting the BTK-JAK Axis in Preclinical Models of Rat Collagen-Induced Arthritis with GS-4059 in Combination with a JAK Inhibitor [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/targeting-the-btk-jak-axis-in-preclinical-models-of-rat-collagen-induced-arthritis-with-gs-4059-in-combination-with-a-jak-inhibitor/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/targeting-the-btk-jak-axis-in-preclinical-models-of-rat-collagen-induced-arthritis-with-gs-4059-in-combination-with-a-jak-inhibitor/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology